Avanços e desafios da imunoterapia no tratamento de gliomas
Nenhuma Miniatura disponível
Data
2023-12
Tipo de documento
Artigo Científico
Título da Revista
ISSN da Revista
Título de Volume
Área do conhecimento
Modalidade de acesso
Acesso fechado
Editora
Autores
CORRÊA, Débora Caroline Gonçalves
PAIXÃO, Priscila dos Anjos Muniz
Orientador
TOBIAS, Alessandra Hermógenes Gomes
Coorientador
PEREIRA, Ramon de Alencar
Resumo
Introdução: Os Gliomas são um conjunto de tumores do sistema nervoso central que estão associados a elevadas taxas de mortalidade, baixa expectativa de vida e alta recorrência. O diagnóstico tardio e o tratamento convencional não eficaz revelam uma necessidade urgente de novas estratégias terapêuticas. Objetivo: Avaliar na literatura a resposta de imunoterápicos em pacientes diagnosticados com glioma. Método: Trata-se de uma revisão da literatura realizada por meio da seleção de artigos nas bases de dados SciELO, PubMed, Biblioteca Virtual da Saúde com as palavras-chaves Gliomas. Immunotherapy Gliomas. Immune Checkpoints. Resultados: As abordagens imunoterápicas são crescentes na literatura, as classes dos inibidores dos pontos de controle imunológicos têm sido utilizados no combate aos tumores do sistema nervoso central devido a evasão tumoral associada às proteínas PD-1/PD-L1 e CTLA-4. As imunoterapias, associadas ou não, têm sido estudadas a fim de explorar as fraquezas dos gliomas e direcionar estratégias para o tratamento. Conclusão: O uso da terapia imunoterápica tem alcançado resultados promissores, contudo, o foco nos gliomas apresenta resultados limitados. Novas pesquisas visando a segregação de tumores do sistema nervoso central de acordo com a nova estrutura de diagnóstico da OMS são de extrema relevância para melhorar a compreensão do uso dos imunoterápicos e consequentemente elevar a qualidade de vida e as perspectivas de tratamento dos pacientes.
Introduction: Gliomas are a group of tumors of the central nervous system that are associated with high mortality rates, low life expectancy and high recurrence. Late diagnosis and ineffective conventional treatment reveal an urgent need for new therapeutic strategies. Objective: To evaluate the response to immunotherapy in patients diagnosed with glioma in the literature. Method: This is a literature review carried out by selecting articles from the SciELO, PubMed, VHL databases with the keywords Gliomas, Immunotherapy Gliomas, Immune Checkpoints. Results: Immunotherapeutic approaches are growing in the literature, classes of immune checkpoint inhibitors have been used to combat tumors of the central nervous system due to tumor evasion associated with PD-1/PD-L1 and CTLA-4 proteins. Associated or non-associated immunotherapies has been studies in order to exploit the weaknesses of gliomas and target treatment strategies. Conclusion: The use of immunotherapy has achieved promising results; however, but the focus on gliomas shows limited results. New research aimed at segregating tumors of the central nervous system according to the new WHO diagnostic framework is extremely important to improve understanding of the use of immunotherapies and consequently increase the quality of life and prospects for patients.
Introduction: Gliomas are a group of tumors of the central nervous system that are associated with high mortality rates, low life expectancy and high recurrence. Late diagnosis and ineffective conventional treatment reveal an urgent need for new therapeutic strategies. Objective: To evaluate the response to immunotherapy in patients diagnosed with glioma in the literature. Method: This is a literature review carried out by selecting articles from the SciELO, PubMed, VHL databases with the keywords Gliomas, Immunotherapy Gliomas, Immune Checkpoints. Results: Immunotherapeutic approaches are growing in the literature, classes of immune checkpoint inhibitors have been used to combat tumors of the central nervous system due to tumor evasion associated with PD-1/PD-L1 and CTLA-4 proteins. Associated or non-associated immunotherapies has been studies in order to exploit the weaknesses of gliomas and target treatment strategies. Conclusion: The use of immunotherapy has achieved promising results; however, but the focus on gliomas shows limited results. New research aimed at segregating tumors of the central nervous system according to the new WHO diagnostic framework is extremely important to improve understanding of the use of immunotherapies and consequently increase the quality of life and prospects for patients.
Palavras-chave
gliomas, immunotherapy gliomas, immune checkpoints